Cargando…
L-alanine supplementation in Pompe disease (IOPD): a potential therapeutic implementation for patients on ERT? A case report
BACKGROUND: Pompe disease (PD) is a disorder of glycogen metabolism conditioning a progressive and life conditioning myopathy. Enzyme replacement therapy (ERT) is currently the best treatment option for PD, but is not resolutive. While other potential therapeutic approaches have been reported before...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8962230/ https://www.ncbi.nlm.nih.gov/pubmed/35346323 http://dx.doi.org/10.1186/s13052-022-01249-y |
_version_ | 1784677752479154176 |
---|---|
author | Rovelli, Valentina Zuvadelli, Juri Piotto, Marta Scopari, Andrea Dionigi, Alice Re Ercoli, Vittoria Paci, Sabrina Cefalo, Graziella Salvatici, Elisabetta Banderali, Giuseppe |
author_facet | Rovelli, Valentina Zuvadelli, Juri Piotto, Marta Scopari, Andrea Dionigi, Alice Re Ercoli, Vittoria Paci, Sabrina Cefalo, Graziella Salvatici, Elisabetta Banderali, Giuseppe |
author_sort | Rovelli, Valentina |
collection | PubMed |
description | BACKGROUND: Pompe disease (PD) is a disorder of glycogen metabolism conditioning a progressive and life conditioning myopathy. Enzyme replacement therapy (ERT) is currently the best treatment option for PD, but is not resolutive. While other potential therapeutic approaches have been reported before, these have never been tried as co- treatments. L-alanine oral supplementation (LAOS) has been proven to reduce muscle breakdown: we hereby report the first case of supplementation on a PD patient on ERT. CASE PRESENTATION: F. is a 9 y.o. infantile onset Pompe Disease (IOPD) girl ERT-treated since age 1 developing a progressive myopathy. We started her on LAOS and performed assessments at baseline, 6 and 9 months. At baseline, F.’s weight, height and BMI were within normal ranges, while body composition showed low fat mass -FM and high resting energy expenditure—REE levels. After LAOS, a progressive FM increase and REE reduction could be observed both at 6 and 9 months. CONCLUSIONS: ERT is not curative for PD patients thus additional treatments could be considered to improve outcomes. Our patient showed physical signs of inability to accumulate energy when exclusively on ERT, while FM increase and REE reduction occurred when supplemented with LAOS, likely reflecting anabolic pathways’ implementation. This is the first case reporting potential LAOS benefits in PD-on ERT patients. Longitudinal case control studies are yet needed to evaluate possible efficacy of combined LAOS And ERT treatment in PD patients. |
format | Online Article Text |
id | pubmed-8962230 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-89622302022-03-30 L-alanine supplementation in Pompe disease (IOPD): a potential therapeutic implementation for patients on ERT? A case report Rovelli, Valentina Zuvadelli, Juri Piotto, Marta Scopari, Andrea Dionigi, Alice Re Ercoli, Vittoria Paci, Sabrina Cefalo, Graziella Salvatici, Elisabetta Banderali, Giuseppe Ital J Pediatr Case Report BACKGROUND: Pompe disease (PD) is a disorder of glycogen metabolism conditioning a progressive and life conditioning myopathy. Enzyme replacement therapy (ERT) is currently the best treatment option for PD, but is not resolutive. While other potential therapeutic approaches have been reported before, these have never been tried as co- treatments. L-alanine oral supplementation (LAOS) has been proven to reduce muscle breakdown: we hereby report the first case of supplementation on a PD patient on ERT. CASE PRESENTATION: F. is a 9 y.o. infantile onset Pompe Disease (IOPD) girl ERT-treated since age 1 developing a progressive myopathy. We started her on LAOS and performed assessments at baseline, 6 and 9 months. At baseline, F.’s weight, height and BMI were within normal ranges, while body composition showed low fat mass -FM and high resting energy expenditure—REE levels. After LAOS, a progressive FM increase and REE reduction could be observed both at 6 and 9 months. CONCLUSIONS: ERT is not curative for PD patients thus additional treatments could be considered to improve outcomes. Our patient showed physical signs of inability to accumulate energy when exclusively on ERT, while FM increase and REE reduction occurred when supplemented with LAOS, likely reflecting anabolic pathways’ implementation. This is the first case reporting potential LAOS benefits in PD-on ERT patients. Longitudinal case control studies are yet needed to evaluate possible efficacy of combined LAOS And ERT treatment in PD patients. BioMed Central 2022-03-28 /pmc/articles/PMC8962230/ /pubmed/35346323 http://dx.doi.org/10.1186/s13052-022-01249-y Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Case Report Rovelli, Valentina Zuvadelli, Juri Piotto, Marta Scopari, Andrea Dionigi, Alice Re Ercoli, Vittoria Paci, Sabrina Cefalo, Graziella Salvatici, Elisabetta Banderali, Giuseppe L-alanine supplementation in Pompe disease (IOPD): a potential therapeutic implementation for patients on ERT? A case report |
title | L-alanine supplementation in Pompe disease (IOPD): a potential therapeutic implementation for patients on ERT? A case report |
title_full | L-alanine supplementation in Pompe disease (IOPD): a potential therapeutic implementation for patients on ERT? A case report |
title_fullStr | L-alanine supplementation in Pompe disease (IOPD): a potential therapeutic implementation for patients on ERT? A case report |
title_full_unstemmed | L-alanine supplementation in Pompe disease (IOPD): a potential therapeutic implementation for patients on ERT? A case report |
title_short | L-alanine supplementation in Pompe disease (IOPD): a potential therapeutic implementation for patients on ERT? A case report |
title_sort | l-alanine supplementation in pompe disease (iopd): a potential therapeutic implementation for patients on ert? a case report |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8962230/ https://www.ncbi.nlm.nih.gov/pubmed/35346323 http://dx.doi.org/10.1186/s13052-022-01249-y |
work_keys_str_mv | AT rovellivalentina lalaninesupplementationinpompediseaseiopdapotentialtherapeuticimplementationforpatientsonertacasereport AT zuvadellijuri lalaninesupplementationinpompediseaseiopdapotentialtherapeuticimplementationforpatientsonertacasereport AT piottomarta lalaninesupplementationinpompediseaseiopdapotentialtherapeuticimplementationforpatientsonertacasereport AT scopariandrea lalaninesupplementationinpompediseaseiopdapotentialtherapeuticimplementationforpatientsonertacasereport AT dionigialicere lalaninesupplementationinpompediseaseiopdapotentialtherapeuticimplementationforpatientsonertacasereport AT ercolivittoria lalaninesupplementationinpompediseaseiopdapotentialtherapeuticimplementationforpatientsonertacasereport AT pacisabrina lalaninesupplementationinpompediseaseiopdapotentialtherapeuticimplementationforpatientsonertacasereport AT cefalograziella lalaninesupplementationinpompediseaseiopdapotentialtherapeuticimplementationforpatientsonertacasereport AT salvaticielisabetta lalaninesupplementationinpompediseaseiopdapotentialtherapeuticimplementationforpatientsonertacasereport AT banderaligiuseppe lalaninesupplementationinpompediseaseiopdapotentialtherapeuticimplementationforpatientsonertacasereport |